HALB (Halberd) Other Financing: $0.00 Mil (TTM As of Jul. 2023)


What is Halberd Other Financing?

Halberd HALB -1.05% Other Financing is $0.00 Mil as of Jul. 2023.

Halberd's Other Financing for the six months ended in Jul. 2023 was $0.00 Mil.

Halberd's Other Financing for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

Halberd Other Financing Historical Data

* Premium members only.

The historical data trend for Halberd's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halberd Other Financing Chart

Halberd Annual Data
Trend Jul08 Jul22 Jul23
Other Financing
0.00 0.00 0.00

Halberd Semi-Annual Data
Jul08 Jul22 Jul23
Other Financing 0.00 0.00 0.00

Halberd Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Other Financing for the trailing twelve months (TTM) ended in Jul. 2023 was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
Halberd (HALB) has a Other Financing of $0.00 Mil as of Jul. 2023. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Halberd and its competitors.
Is Halberd's Other Financing too high?
Halberd's current Other Financing is $0.00 Mil.
How does Halberd's Other Financing compare to GRI and OCEA?
Halberd's Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Halberd and its competitors. Halberd's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Halberd stock overvalued right now?
Halberd (HALB) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Halberd (HALB), the current Other Financing is $0.00 Mil as of Jul. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Halberd Business Description

Address P.O. Box 25, Jackson Center, PA, USA, 16133
Halberd Corp is a holding company and acquisition vehicle for established businesses. It is also developing a patented process for disease eradication by removing the pathophysiologic basis of the disease. The company is focused on developing treatments for neurodegenerative diseases, such as PTSD and CTE (Post Traumatic Stress Disorder and Chronic Traumatic Encephalopathy), Alzheimer's Disease, Parkinson's Disease, etc.